Breaking News

AbilityPharma Completes €7M Investment Round

Funding will allow the company to fully finance its phase 2b clinical study of antitumor compound ABTL0812 in patients with pancreatic cancer.

Author Image

By: Charlie Sternberg

Associate Editor

Ability Pharmaceuticals, SA, a biopharmaceutical company focused on the development of innovative oral autophagy-inducing anticancer compounds, has announced a €7M ($7.7M) investment from a European-Canadian syndicate of life sciences investors, which will allow the company to fully finance its phase 2b clinical study of antitumor compound ABTL0812 in patients with pancreatic cancer.   AbilityPharma is completing the Phase 2b clinical trial with ABTL0812 with the aim of demonstrating greater e...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters